V L Franklin1, F Khan, G Kennedy, J J F Belch, S A Greene. 1. Maternal and Child Health Sciences, University of Dundee, Ninewells Hospital and Medical School, Dundee, UK. victoria.franklin@nhs.net
Abstract
AIMS/HYPOTHESIS: Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes, and this vascular impairment begins in childhood. The aim of this study was to determine whether introducing intensive diabetes management [intensive insulin therapy (IIT) and 'Sweet Talk' text-messaging support] produces measurable improvements in endothelial function. METHODS:One hundred and twenty-six patients fulfilled the eligibility criteria (type 1 diabetes for >1 year; on conventional insulin therapy (CIT); aged between 8 and 18 years), of whom 92 enrolled. Patients were randomised to group 1, CIT only (n=28); group 2, CIT and Sweet Talk (n=33); or group 3, IIT and Sweet Talk (n=31). Vascular assessments (including measures of endothelial damage, activation, dysfunction and oxidative stress) and HbA1c were performed at baseline and repeated after 12 months of the study. RESULTS:Glycaemic control deteriorated in patients on CIT, but improved significantly in patients allocated to IIT (p=0.007). IIT was associated with significantly greater improvements in E-selectin (p<0.0001) than CIT (group 1, p=0.026 and group 2, p=0.053). Vascular responses to acetylcholine improved in patients on IIT (p=0.017), but not in patients receiving CIT. These changes were all independent of HbA1c level. CONCLUSIONS/ INTERPRETATION: IIT appears to be associated with improvements in vascular markers, independently of changes in HbA1c, suggesting that IIT may confer vascular protection in addition to improving glycaemic control.
RCT Entities:
AIMS/HYPOTHESIS: Macrovascular disease is an important cause of the increased morbidity and mortality rates associated with type 1 diabetes, and this vascular impairment begins in childhood. The aim of this study was to determine whether introducing intensive diabetes management [intensive insulin therapy (IIT) and 'Sweet Talk' text-messaging support] produces measurable improvements in endothelial function. METHODS: One hundred and twenty-six patients fulfilled the eligibility criteria (type 1 diabetes for >1 year; on conventional insulin therapy (CIT); aged between 8 and 18 years), of whom 92 enrolled. Patients were randomised to group 1, CIT only (n=28); group 2, CIT and Sweet Talk (n=33); or group 3, IIT and Sweet Talk (n=31). Vascular assessments (including measures of endothelial damage, activation, dysfunction and oxidative stress) and HbA1c were performed at baseline and repeated after 12 months of the study. RESULTS: Glycaemic control deteriorated in patients on CIT, but improved significantly in patients allocated to IIT (p=0.007). IIT was associated with significantly greater improvements in E-selectin (p<0.0001) than CIT (group 1, p=0.026 and group 2, p=0.053). Vascular responses to acetylcholine improved in patients on IIT (p=0.017), but not in patients receiving CIT. These changes were all independent of HbA1c level. CONCLUSIONS/ INTERPRETATION: IIT appears to be associated with improvements in vascular markers, independently of changes in HbA1c, suggesting that IIT may confer vascular protection in addition to improving glycaemic control.
Authors: T A Elhadd; G Kennedy; A Hill; M McLaren; R W Newton; S A Greene; J J Belch Journal: Diabetes Metab Res Rev Date: 1999 Nov-Dec Impact factor: 4.876
Authors: S P Laing; A J Swerdlow; S D Slater; J L Botha; A C Burden; N R Waugh; A W Smith; R D Hill; P J Bingley; C C Patterson; Z Qiao; H Keen Journal: Diabet Med Date: 1999-06 Impact factor: 4.359
Authors: H B Mortensen; K J Robertson; H J Aanstoot; T Danne; R W Holl; P Hougaard; J A Atchison; F Chiarelli; D Daneman; B Dinesen; H Dorchy; P Garandeau; S Greene; H Hoey; E A Kaprio; M Kocova; P Martul; N Matsuura; E J Schoenle; O Søvik; P G Swift; R M Tsou; M Vanelli; J Aman Journal: Diabet Med Date: 1998-09 Impact factor: 4.359
Authors: R G IJzerman; R T de Jongh; M A M Beijk; M M van Weissenbruch; H A Delemarre-van de Waal; E H Serné; C D A Stehouwer Journal: Eur J Clin Invest Date: 2003-07 Impact factor: 4.686
Authors: Faisel Khan; Fiona C Green; J Stewart Forsyth; Stephen A Greene; Andrew D Morris; Jill J F Belch Journal: J Physiol Date: 2003-06-24 Impact factor: 5.182
Authors: Richard S Beard; Brian A Hoettels; Jamie E Meegan; Travis S Wertz; Byeong J Cha; Xiaoyuan Yang; Julia T Oxford; Mack H Wu; Sarah Y Yuan Journal: J Cereb Blood Flow Metab Date: 2018-12-21 Impact factor: 6.200
Authors: Marcello C Bertoluci; Gislaine V Cé; Antônio Mv da Silva; Marco V Wainstein; Winston Boff; Marcia Puñales Journal: World J Diabetes Date: 2015-06-10
Authors: N Minuto; V Emmanuele; M Vannati; C Russo; C Rebora; S Panarello; A Pistorio; R Lorini; G d'Annunzio Journal: J Endocrinol Invest Date: 2011-10-06 Impact factor: 4.256